David Lebovitz
Stock Analyst at Citigroup
(3.17)
# 976
Out of 4,818 analysts
94
Total ratings
62.5%
Success rate
5.32%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Lebovitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $338 → $351 | $242.16 | +44.95% | 31 | Mar 21, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $378 → $469 | $309.32 | +51.62% | 4 | Feb 27, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Neutral | $81 → $82 | $62.02 | +32.23% | 3 | Feb 20, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Buy | $70 → $74 | $32.49 | +127.80% | 2 | Nov 14, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $37 → $38 | $39.61 | -4.06% | 1 | May 9, 2024 | |
| PTCT PTC Therapeutics | Downgrades: Sell | $29 → $17 | $50.05 | -66.03% | 5 | Oct 27, 2023 | |
| BPMC Blueprint Medicines | Maintains: Equal-Weight | $111 → $92 | $85.93 | +7.06% | 6 | Feb 1, 2022 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $57 → $54 | $60.11 | -10.16% | 5 | Aug 4, 2021 | |
| IONS Ionis Pharmaceuticals | Maintains: Underweight | $38 → $35 | $29.09 | +20.32% | 6 | May 6, 2021 | |
| MGNX MacroGenics | Maintains: Underweight | $16 → $17 | $1.71 | +894.15% | 11 | Apr 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $11 | $0.77 | +1,321.92% | 7 | Feb 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $194 → $199 | $158.46 | +25.58% | 11 | Nov 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $510 → $480 | $6.33 | +7,482.94% | 2 | Nov 3, 2020 |
Alnylam Pharmaceuticals
Mar 21, 2025
Maintains: Buy
Price Target: $338 → $351
Current: $242.16
Upside: +44.95%
Madrigal Pharmaceuticals
Feb 27, 2025
Maintains: Buy
Price Target: $378 → $469
Current: $309.32
Upside: +51.62%
BioMarin Pharmaceutical
Feb 20, 2025
Maintains: Neutral
Price Target: $81 → $82
Current: $62.02
Upside: +32.23%
Crinetics Pharmaceuticals
Nov 14, 2024
Maintains: Buy
Price Target: $70 → $74
Current: $32.49
Upside: +127.80%
Mirum Pharmaceuticals
May 9, 2024
Maintains: Buy
Price Target: $37 → $38
Current: $39.61
Upside: -4.06%
PTC Therapeutics
Oct 27, 2023
Downgrades: Sell
Price Target: $29 → $17
Current: $50.05
Upside: -66.03%
Blueprint Medicines
Feb 1, 2022
Maintains: Equal-Weight
Price Target: $111 → $92
Current: $85.93
Upside: +7.06%
Rhythm Pharmaceuticals
Aug 4, 2021
Maintains: Overweight
Price Target: $57 → $54
Current: $60.11
Upside: -10.16%
Ionis Pharmaceuticals
May 6, 2021
Maintains: Underweight
Price Target: $38 → $35
Current: $29.09
Upside: +20.32%
MacroGenics
Apr 30, 2021
Maintains: Underweight
Price Target: $16 → $17
Current: $1.71
Upside: +894.15%
Feb 22, 2021
Maintains: Equal-Weight
Price Target: $12 → $11
Current: $0.77
Upside: +1,321.92%
Nov 13, 2020
Maintains: Overweight
Price Target: $194 → $199
Current: $158.46
Upside: +25.58%
Nov 3, 2020
Maintains: Overweight
Price Target: $510 → $480
Current: $6.33
Upside: +7,482.94%